庚烷-2,4-二醇 | 20748-86-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 庚烷-2,4-二醇
• 英文名称: heptane-2,4-diol
• 英文别名: Heptan-2,4-diol；2,4-heptanediol；Heptandiol-(2,4)；Heptandiol-2,4
• CAS: 20748-86-1
• 化学式: C₇H₁₆O₂
• 分子量: 132.203
• InChiKey: XVEOUOTUJBYHNL-UHFFFAOYSA-N

物化性质

• 熔点：
  44.24°C (estimate)
• 沸点：
  233.16°C (rough estimate)
• 密度：
  0.9328
• 保留指数：
  1051

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  庚烷-2,4-二醇 、 苯甲酰氯 在 吡啶 作用下， 生成 2,4-bis-benzoyloxy-heptane
  参考文献：
  名称：

  Über对二甲基氨基苯甲酮III。Zur Kenntnis der auxochromen Gruppen

  摘要：

  DOI：

  10.1002/hlca.193201501156
• 作为产物：
  描述：

  2,6-二甲基-4-吡喃酮 在 镍 氢气 作用下， 以 乙醇 为溶剂， 100.0 ℃ 、9.81 MPa 条件下， 生成 庚烷-2,4-二醇
  参考文献：
  名称：

  Riobe,O. et al., Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1963, vol. 256, p. 1542 - 1544

  摘要：

  DOI：

文献信息

• MATERIAL FOR FORMING ORGANIC FILM, METHOD FOR FORMING ORGANIC FILM, PATTERNING PROCESS, AND COMPOUND
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20210286266A1

  公开（公告）日：2021-09-16

  The present invention is a material for forming an organic film, including: a compound shown by the following general formula (1); and an organic solvent, where in the general formula (1), X represents an organic group with a valency of “n” having 2 to 50 carbon atoms or an oxygen atom, “n” represents an integer of 1 to 10 , and R 1 independently represents any of the following general formulae (2), where in the general formulae (2), broken lines represent attachment points to X, and Q 1 represents a monovalent organic group containing a carbonyl group, at least a part of which is a group shown by the following general formulae (3), where in the general formulae (3), broken lines represent attachment points, X 1 represents a single bond or a divalent organic group having 1 to 20 carbon atoms optionally having a substituent when the organic group has an aromatic ring, R 2 represents a hydrogen atom, a methyl group, an ethyl group, or a phenyl group, and ** represents an attachment point. An object of the present invention is to provide a material for forming an organic film for forming an organic film having dry etching resistance, and also having high filling and planarizing properties and adhesion to a substrate.

  本发明是一种用于形成有机薄膜的材料，包括：由以下通用式（1）所示的化合物；和有机溶剂，在通用式（1）中，X代表具有2至50个碳原子或一个氧原子的价为“n”的有机基团，“n”表示1到10的整数，R1独立地表示以下通用式（2）中的任何一种，其中在通用式（2）中，虚线表示连接点到X，Q1表示含有羰基的一价有机基团，其中至少部分是以下通用式（3）所示的基团，其中在通用式（3）中，虚线表示连接点，X1表示单键或具有1到20个碳原子的二价有机基团，在有机基团具有芳香环时可选地具有取代基，R2表示氢原子、甲基基团、乙基基团或苯基团，**表示连接点。本发明的目的是提供一种用于形成具有干法刻蚀抗性的有机薄膜的材料，同时具有高填充和平整化性能以及对基底的粘附性。
• [EN] RENEWABLE FURAN BASED AMINE CURING AGENTS FOR EPOXY THERMOSET<br/>[FR] AGENTS DE DURCISSEMENT AMINE À BASE DE FURANE RENOUVELABLE POUR PLASTIQUE ÉPOXYDIQUE THERMODURCISSABLE
  申请人：PALMESE GIUSEPPE R

  公开号：WO2019040389A1

  公开（公告）日：2019-02-28

  The present invention relates novel furan based amine cross-linkers with improved thermomechanical and water barrier properties. The novelty of this invention is the use of aromatic, and hydrophobic aliphatic aldehydes to bridge two furfuryl amines, which yields a diamine or tetra amines with a significantly enhanced hydrophobic character. These diamine cross-linkers exhibit enhanced water barrier properties and thermomechanical properties when cured with both commercial and synthetic epoxies.

  这项发明涉及一种具有改进的热机械和防水性能的新型呋喃基胺交联剂。该发明的新颖之处在于使用芳香族和疏水脂肪族醛来连接两个呋喃基胺，从而产生具有显著增强疏水性质的二胺或四胺。这些二胺交联剂在与商业和合成环氧树脂一起固化时表现出增强的防水性能和热机械性能。
• [EN] SYNTHESIS OF HIGH CALORIC FUELS AND CHEMICALS<br/>[FR] SYNTHÈSE DE COMBUSTIBLES ET DE PRODUITS CHIMIQUES À FORT POUVOIR CALORIFIQUE
  申请人：PIONEER ENERGY

  公开号：WO2013070966A1

  公开（公告）日：2013-05-16

  In one embodiment, the present application discloses methods to selectively synthesize higher alcohols and hydrocarbons useful as fuels and industrial chemicals from syngas and biomass. Ketene and ketonization chemistry along with hydrogenation reactions are used to synthesize fuels and chemicals. In another embodiment, ketene used to form fuels and chemicals may be manufactured from acetic acid which in turn can be synthesized from synthesis gas which is produced from coal, biomass, natural gas, etc.

  在一种实施例中，本申请公开了一种从合成气和生物质中选择性合成高级醇类和烃类的方法，这些物质可用作燃料和工业化学品。酮烯和酮化学以及加氢反应被用来合成燃料和化学品。在另一种实施例中，用于形成燃料和化学品的酮烯可以从乙酸制造，而乙酸可以从煤、生物质、天然气等生产的合成气中合成。
• PHOTORESIST COMPOSITION, RESIST-PATTERN FORMING METHOD, POLYMER, AND COMPOUND
  申请人：SATO Mitsuo

  公开号：US20120258402A1

  公开（公告）日：2012-10-11

  A photoresist composition includes a polymer that includes a structural unit shown by the following formula (1), and a photoacid generator. R 1 in the formula (1) represents a hydrogen atom, a fluorine atom, a methyl group, or a trifluoromethyl group, Z represents a group that forms a divalent alicyclic group having 3 to 20 carbon atoms together with a carbon atom bonded to X, X represents an alkanediyl group having 1 to 6 carbon atoms, Y represents a hydrogen atom or —CR 2 R 3 (OR 4 ), and R 2 to R 4 independently represent a hydrogen atom or a monovalent hydrocarbon group, provided that R 3 and R 4 optionally bond to each other to form a cyclic ether structure together with a carbon atom bonded to R 3 and an oxygen atom bonded to R 4 .

  一种光阻剂组合物包括一个聚合物，该聚合物包括下式（1）所示的结构单元，以及一个光酸发生剂。在式（1）中，R1代表氢原子、氟原子、甲基基团或三氟甲基基团，Z代表与与X键合的碳原子一起形成具有3到20个碳原子的二价脂环族基团，X代表具有1到6个碳原子的脂肪二基基团，Y代表氢原子或—CR2R3(OR4)，R2到R4独立地代表氢原子或一价烃基团，其中R3和R4可选择地相互键合以与与R3键合的碳原子和与R4键合的氧原子一起形成环状醚结构。
• Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy
  作者：Gary Milkovich、Ronald J. Moleski、John F. Reitan、David M. Dunning、Gene A. Gibson、Thomas A. Paivanas、Susan Wyant、R. Jake Jacobs

  DOI：10.1592/phco.20.19.1432.34861

  日期：2000.12

  Study Objective. To compare rates of adverse events with filgrastim versus sargramostim when given prophylactically to patients receiving myelosuppressive chemotherapy. Design. Retrospective review with center crossover. Setting. Ten United States outpatient chemotherapy centers. Patients. Four hundred ninety patients treated for lung, breast, lymphatic system, or ovarian tumors. Intervention. Prophylactic use of filgrastim or sargramostim, with dosages at investigator discretion. Measurements and Main Results. The frequency and severity of adverse events and the frequency of switching to the alternative CSF were assessed. There was no difference in infectious fever. Fever unexplained by infection was more common with sargramostim (7% vs 1%, p<0.001), as were fatigue, diarrhea, injection site reactions, other dermatologic disorders, and edema (all p<0.05). Skeletal pain was more frequent with filgrastim (p=0.06). Patients treated with sargramostim switched to the alternative agent more often (p<0.001). Conclusion. Adverse events were less frequent with filgrastim than with sargramostim, suggesting that quality of life and treatment costs also may differ.

  研究目的：比较在接受骨髓抑制化疗的患者中，预防性使用菲尔格司亭与沙格莫司亭的副作用发生率。 设计：回顾性研究，具有中心交叉设计。 设置：美国十个门诊化疗中心。 患者：490名接受肺癌、乳腺癌、淋巴系统或卵巢肿瘤治疗的患者。 干预：在研究者的判断下，预防性使用菲尔格司亭或沙格莫司亭，剂量由研究者自行决定。 测量与主要结果：评估了副作用的发生频率和严重程度，以及转用替代性粒细胞生长因子的频率。感染引起的发热没有差异。与沙格莫司亭相比，不明原因的发热更为常见（7%对1%，p<0.001），疲劳、腹泻、注射部位反应、其他皮肤病和水肿也更常见（均p<0.05）。骨骼疼痛在使用菲尔格司亭的患者中更为频繁（p=0.06）。接受沙格莫司亭治疗的患者更常转用替代药物（p<0.001）。 结论：与沙格莫司亭相比，使用菲尔格司亭的副作用发生率更低，这表明生活质量和治疗费用也可能存在差异。